Lundbeck is currently marketing five products in the United States for Hematology/Oncology-related disease and disorders.

• ATryn® (Antithrombin [Recombinant])
• Cosmegen® for Injection (dactinomycin for injection) †
• Elspar® (asparaginase)
• Mustargen® (mechlorethamine HCl for injection)†
• Panhematin® (hemin for injection)†    

To learn more about these products, including full prescribing information and applicable boxed warnings (^† ), please visit the individual product pages. included on this website.

 

________________________________________________________________________

ATryn Indications and Usage:

ATryn [Antithrombin (Recombinant)] is indicated for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

It is not indicated for treatment of thromboembolic events in hereditary antithrombin deficient patients.

Important Safety Information:
ATrynis contraindicated in patients with known hypersensitivity to goat and goat milk proteins.

Allergic-type hypersensitivity reactions are possible. Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis. If these symptoms occur during administration, treatment must be discontinued immediately. Adding ATryn to or withdrawing ATryn from anticoagulants that use antithrombin to exert their anticoagulative effects may alter this effect. To avoid excessive or insufficient anticoagulation, coagulation tests suitable for the anticoagulant used (e.g., aPTT and anti-Factor Xa activity) are to be performed regularly, at close intervals, and in particular in the first hours following the start or withdrawal of ATryn. In such situations, patients should be monitored for the occurrence of bleeding or thrombosis.

The serious adverse reaction that has been reported in clinical studies is hemorrhage (intra-abdominal, hemarthrosis, and post procedural). The most common adverse events reported in clinical trials at a frequency of >5% are hemorrhage and infusion site reaction.

For more information, please see Full Prescribing Information.

® Trademark of Lundbeck Inc., Deerfield, IL 60015, U.S.A.